Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Postmarket Surveillance, 20604-20606 [2010-8977]
Download as PDF
20604
Federal Register / Vol. 75, No. 75 / Tuesday, April 20, 2010 / Notices
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Title: Tobacco Health Document
Submission (OMB Control Number
0910–0654)—Extension
On June 22, 2009, the President
signed the Tobacco Control Act (Public
Law 111–31) into law. The Tobacco
Control Act granted FDA important new
authority to regulate the manufacture,
marketing, and distribution of tobacco
products to protect the public health
generally and to reduce tobacco use by
minors. Among its many provisions, the
Tobacco Control Act added section
904(a)(4) to the Federal Food, Drug, and
Cosmetic Act (the act) (21 U.S.C.
387d(a)(4)), requiring submission of
documents related to certain effects of
tobacco products.
Section 904(a)(4) of the act requires
each tobacco product manufacturer or
importer, or agent thereof, to submit all
documents developed after June 22,
2009 ‘‘that relate to health, toxicological,
behavioral, or physiologic effects of
current or future tobacco products, their
constituents (including smoke
constituents), ingredients, components,
and additives.’’ Information required
under section 904(a)(4) of the act must
be submitted to FDA beginning
December 22, 2009.
FDA issued a draft guidance
document entitled, ‘‘Tobacco Health
Document Submission’’ on December
28, 2009 (74 FR 68629) to assist persons
making certain document submissions
to FDA under section 904(a)(4) of the
act. While electronic submission of
tobacco health documents is not
required, FDA designed the eSubmitter
application as an alternative for mailing
documents. This electronic tool allows
for importation of large quantities of
structured data, attachments of files
(e.g., in portable document format
(PDFs) and certain media files), and
automatic acknowledgement of FDA’s
receipt of submissions. FDA also is
developing a paper form (FDA Form
3743) as an alternative submission tool.
Both the eSubmitter application and the
paper form can be accessed at https://
www.fda.gov/tobacco once they are
complete.
On September 1, 2009 (74 FR 45219),
FDA published notice in the Federal
Register announcing that a proposed
collection of information had been
submitted to OMB for emergency
processing under the Paperwork
Reduction Act of 1995. On September
15, 2009 (74 FR 47257), FDA published
a notice correcting the length of the
comment period, keeping it open until
October 1, 2009. On October 13, 2009
(74 FR 52495), FDA published a notice
reopening the comment period until
October 26, 2009. On January 7, 2010,
FDA received emergency approval for
this information collection. Based on
comments indicating that the burden
estimate was too low, FDA has adjusted
its original burden estimate from 1.0
hour per response to 200 hours per
response. FDA also increased the annual
frequency per response from 1 to 4
(quarterly). FDA is maintaining the
original estimate of the number of
respondents at 10. FDA is basing its
estimates on the total number of tobacco
firms it is aware of, its experience with
document production, and comments
received in response to the draft
guidance document published on
December 28, 2009.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
Activity
No. of Respondents
Tobacco Health Document Submission
1 There
10
ACTION:
4
Hours
per Response
40
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
DATES: Fax written comments on the
collection of information by May 20,
2010.
[Docket No. FDA–2010–N–0033]
Food and Drug Administration,
VerDate Nov<24>2008
14:55 Apr 19, 2010
Jkt 220001
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or e-mailed to
oira_submission@eop.gov. All
ADDRESSES:
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Postmarket
Surveillance
HHS.
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995
(the PRA).
[FR Doc. 2010–8976 Filed 4–19–10; 8:45 am]
erowe on DSK5CLS3C1PROD with NOTICES
Total Annual
Responses
Total Hours
200
8,000
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: April 14, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
AGENCY:
Annual Frequency
per Response
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
comments should be identified with the
OMB control number 0910–0449. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, email:
Daniel.Gittleson@fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\20APN1.SGM
20APN1
20605
Federal Register / Vol. 75, No. 75 / Tuesday, April 20, 2010 / Notices
Postmarket Surveillance—21 CFR Part
822 (OMB Control Number 0910–
0449)—Extension
Section 522(a) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 360l)
authorizes FDA to require
manufacturers to conduct postmarket
surveillance (PS) of any device that
meets the criteria set forth in the statute.
The PS regulation establishes
procedures that FDA uses to approve
and disapprove PS plans. The regulation
provides instructions to manufacturers
so they know what information is
required in a PS plan submission. FDA
reviews PS plan submissions in
accordance with part 822 (21 CFR part
822) in §§ 822.15 to 822.19 of the
regulation, which describe the grounds
for approving or disapproving a PS plan.
In addition, the PS regulation provides
instructions to manufacturers to submit
interim and final reports in accordance
with § 822.38. Respondents to this
collection of information are those
manufacturers who require postmarket
surveillance of their products.
Explanation of Reporting Burden
Estimate
The burden captured in table 1 of this
document for each of these responses is
based on the data available in FDA’s
internal tracking system for 2009. There
was not an internal tracking system
prior to 2009. Sections 822.26, 822.27,
and 822.34 do not constitute
information collection subject to review
under the PRA because ‘‘it entails no
burden other than that necessary to
identify the respondent, the date, the
respondent’s address, and the nature of
the instrument.’’ (5 CFR 1320.3(h)(1)).
Explanation of Recordkeeping Burden
Estimate
FDA expects that at least some of the
manufacturers will be able to satisfy the
PS requirement using information or
data they already have. For purposes of
calculating burden, however, FDA has
assumed that each PS order can only be
satisfied by a 3-year clinically-based
surveillance plan, using three
investigators. These estimates are based
on FDA’s knowledge and experience
with limited implementation of section
522 under the Safe Medical Devices Act.
Therefore, FDA would expect that the
recordkeeping requirements would
apply to a maximum of 21
manufacturers (3 to 4 added each year)
and 30 investigators (3 per surveillance
plan). After 3 years, FDA would expect
these numbers to remain level as the
surveillance plans conducted under the
earliest orders reach completion and
new orders are issued.
In the Federal Register of February 5,
2010 (75 FR 6036), FDA published a 60–
day notice requesting public comment
on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR Section
822.9 and 822.10
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
21
1
21
120
2,520
822.21
5
1
5
40
200
822.28
5
1
5
8
40
822.29
1
1
1
40
40
822.30
1
1
1
40
40
822.38
40
1
40
40
1,600
Total
1 There
4,440
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
21 CFR Section
No. of
Recordkeepers
Annual Frequency
per Recordkeeping
Total Annual
Record
Hours per
Records
Total Hours
822.31
21
1
21
20
420
822.32
63
1
63
5
315
Total
erowe on DSK5CLS3C1PROD with NOTICES
1 There
735
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Nov<24>2008
14:55 Apr 19, 2010
Jkt 220001
PO 00000
Frm 00051
Fmt 4703
Sfmt 9990
E:\FR\FM\20APN1.SGM
20APN1
20606
Federal Register / Vol. 75, No. 75 / Tuesday, April 20, 2010 / Notices
Dated: April 14, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2010–8977 Filed 4–19–10; 8:45 am]
The Agricultural Health Study: A
Prospective Cohort Study of Cancer
and Other Disease Among Men and
Women in Agriculture (NCI);
Correction Notice
BILLING CODE 4160–01–S
The Federal Register notice published
on March 3, 2010 (75 FR 9902)
announcing the proposed collection and
comment request for the project titled,
‘‘The Agricultural Health Study: A
Prospective Cohort Study of Cancer and
Other Disease Among Men and Women
in Agriculture (NCI)’’ was submitted
with errors. The burden table did not
take into account the time related to
complete the Phase III CATI as well as
several telephone calls to schedule
appointments and to follow up with
instructions regarding the biospecimens
collection. The corrected annual
reporting burden is as follows:
TABLE A.12–1—ESTIMATES OF ANNUAL BURDEN HOURS
Estimated annual
number of respondents
Frequency of response
Average time per
response minutes/hour
Phase III Telephone Interview
& Buccal Cell Scripts.
Phase III CATI ..........................
150
1
5/60 (0.083)
12.50
150
1
35/60 (0.583)
87.50
Phase III Buccal Cell Reminder, Missing or Damaged
Scripts.
BEEA CATI Screener ...............
BEEA Home Visit CAPI, Blood,
& Urine x 1.
BEEA Schedule Home Visit
Script.
BEEA Home Visit CAPI, Blood,
& Urine x 3.
150
1
5/60 (0.083)
12.50
960
310
1
1
20/60 (0.33)
20/60 (0.33)
320.00
5.17
10
3
5/60 (0.33)
2.50
10
3
≤ 20/60 (0.33)
10.00
...................................................
1740
............................
............................
450.17
Type of respondent
Instrument
Private Applicators, Spouses,
Commercial Applicators.
Private Applicators, Spouses,
Commercial Applicators.
Private Applicators, Spouses,
Commercial Applicators.
Private Applicators ....................
Private Applicators ....................
Private Applicators ....................
Private Applicators ....................
Total ...................................
Dated: April 14, 2010.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National
Institutes of Health.
DATES: Submit written or electronic
comments on this guidance at any time.
General comments on agency guidance
documents are welcome at any time.
[FR Doc. 2010–9098 Filed 4–19–10; 8:45 am]
Submit written requests for
single copies of the guidance document
entitled ‘‘Tobacco Health Document
Submission’’ to the Center for Tobacco
Products, Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850–3229. Send one
self-addressed adhesive label to assist
that office in processing your request or
include a fax number to which the draft
guidance document may be sent. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance document.
Submit electronic comments to https://
www.regulations.gov. Submit written
comments on the guidance to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Identify comments with the
docket number found in brackets in the
heading of this document.
ADDRESSES:
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–D–0600]
Guidance for Industry on Tobacco
Health Document Submission;
Availability
AGENCY:
Food and Drug Administration,
HHS.
erowe on DSK5CLS3C1PROD with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance entitled
‘‘Tobacco Health Document
Submission.’’ The guidance document is
intended to assist persons making
certain document submissions to FDA
under the Family Smoking Prevention
and Tobacco Control Act (Tobacco
Control Act).
VerDate Nov<24>2008
14:55 Apr 19, 2010
Jkt 220001
FOR FURTHER INFORMATION CONTACT: Beth
Buckler, Center for Tobacco Products,
Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850–
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Annual burden
hours
3229, 1–877–287–1373,
Beth.Buckler@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of December
28, 2009 (74 FR 68629), FDA announced
the availability of a draft guidance
entitled ‘‘Tobacco Health Document
Submission.’’ The agency considered
received comments as it finalized this
guidance. The guidance document is
intended to assist persons making
certain document submissions to FDA
under the Tobacco Control Act (Public
Law 111–31).
The Tobacco Control Act amended
the Federal Food, Drug, and Cosmetic
Act (the act) (21 U.S.C. 301 et seq.) by,
among other things, adding a new
chapter granting FDA important new
authority to regulate the manufacture,
marketing, and distribution of tobacco
products to protect the public health
generally and to reduce tobacco use by
minors. Section 904(a)(4) of the act, as
amended by the Tobacco Control Act,
requires each tobacco product
manufacturer or importer, or agent
thereof, to submit all documents
developed after June 22, 2009 ‘‘that
relate to health, toxicological,
E:\FR\FM\20APN1.SGM
20APN1
Agencies
[Federal Register Volume 75, Number 75 (Tuesday, April 20, 2010)]
[Notices]
[Pages 20604-20606]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-8977]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0033]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Postmarket
Surveillance
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995 (the PRA).
DATES: Fax written comments on the collection of information by May 20,
2010.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or e-mailed to oira_submission@eop.gov. All
comments should be identified with the OMB control number 0910-0449.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-5156, email:
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
[[Page 20605]]
Postmarket Surveillance--21 CFR Part 822 (OMB Control Number 0910-
0449)--Extension
Section 522(a) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 360l) authorizes FDA to require manufacturers to conduct
postmarket surveillance (PS) of any device that meets the criteria set
forth in the statute. The PS regulation establishes procedures that FDA
uses to approve and disapprove PS plans. The regulation provides
instructions to manufacturers so they know what information is required
in a PS plan submission. FDA reviews PS plan submissions in accordance
with part 822 (21 CFR part 822) in Sec. Sec. 822.15 to 822.19 of the
regulation, which describe the grounds for approving or disapproving a
PS plan. In addition, the PS regulation provides instructions to
manufacturers to submit interim and final reports in accordance with
Sec. 822.38. Respondents to this collection of information are those
manufacturers who require postmarket surveillance of their products.
Explanation of Reporting Burden Estimate
The burden captured in table 1 of this document for each of these
responses is based on the data available in FDA's internal tracking
system for 2009. There was not an internal tracking system prior to
2009. Sections 822.26, 822.27, and 822.34 do not constitute information
collection subject to review under the PRA because ``it entails no
burden other than that necessary to identify the respondent, the date,
the respondent's address, and the nature of the instrument.'' (5 CFR
1320.3(h)(1)).
Explanation of Recordkeeping Burden Estimate
FDA expects that at least some of the manufacturers will be able to
satisfy the PS requirement using information or data they already have.
For purposes of calculating burden, however, FDA has assumed that each
PS order can only be satisfied by a 3-year clinically-based
surveillance plan, using three investigators. These estimates are based
on FDA's knowledge and experience with limited implementation of
section 522 under the Safe Medical Devices Act. Therefore, FDA would
expect that the recordkeeping requirements would apply to a maximum of
21 manufacturers (3 to 4 added each year) and 30 investigators (3 per
surveillance plan). After 3 years, FDA would expect these numbers to
remain level as the surveillance plans conducted under the earliest
orders reach completion and new orders are issued.
In the Federal Register of February 5, 2010 (75 FR 6036), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.9 and 822.10 21 1 21 120 2,520
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.21 5 1 5 40 200
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.28 5 1 5 8 40
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.29 1 1 1 40 40
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.30 1 1 1 40 40
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.38 40 1 40 40 1,600
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 4,440
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Table 2.--Estimated Annual Recordkeeping Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Recordkeepers per Recordkeeping Record Records Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.31 21 1 21 20 420
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.32 63 1 63 5 315
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 735
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
[[Page 20606]]
Dated: April 14, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-8977 Filed 4-19-10; 8:45 am]
BILLING CODE 4160-01-S